{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:29:49Z","timestamp":1749155389309,"version":"3.35.0"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 60-year-old man underwent an extended cholecystectomy with regional lymphadenectomy for T2N0M0 gallbladder cancer (GBC), which showed significant FDG uptake (SUV<jats:sub>max<\/jats:sub> = 6.5). However, CT scan at 24 months postsurgery revealed multiple hepatic masses. Unlike the primary GBC, the hepatic masses showed limited FDG uptake (SUV<jats:sub>max<\/jats:sub> = 3.7). A tumor biopsy revealed the diagnosis of a grade 3 neuroendocrine tumor. Furthermore, the hepatic masses showed significant uptake on somatostatin receptor scintigraphy. Upon reevaluation, the primary resected specimen was found to include approximately 10% of neuroendocrine tumor components. This case suggests that different FDG uptake between primary and metastatic cancer may necessitate differential diagnosis.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005539","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T15:02:33Z","timestamp":1730386953000},"page":"e166-e167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic Recurrence of Neuroendocrine Tumor Component in Gallbladder Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Tatsuki","family":"Ikejiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuro","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"bib3-20250203","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00535-021-01827-7","article-title":"JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis","volume":"56","year":"2021","journal-title":"J Gastroenterol"},{"key":"bib4-20250203","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jso.27600","article-title":"Neuroendocrine neoplasms of the gallbladder: a single institute analysis of outcomes and prognostic factors","volume":"129","year":"2024","journal-title":"J Surg Oncol"},{"key":"bib5-20250203","doi-asserted-by":"crossref","first-page":"e12967","DOI":"10.1111\/jne.12967","article-title":"Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms","volume":"33","year":"2021","journal-title":"J Neuroendocrinol"},{"key":"bib6-20250203","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/RLU.0b013e31824d24c4","article-title":"Role of 18F-FDG PET\/CT in detecting recurrent gallbladder carcinoma","volume":"37","year":"2012","journal-title":"Clin Nucl Med"},{"key":"bib7-20250203","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/RLU.0000000000003682","article-title":"Prognostic value of 18F-FDG PET in neuroendocrine neoplasm: a systematic review and meta-analysis","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib8-20250203","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1245\/s10434-015-4471-x","article-title":"Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach","volume":"22","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:01:39Z","timestamp":1738562499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005539","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}